PubMed COVID-19 Clinical Care

This paper aims to revisit the interdependency between business conditions, climate policy change, and the environmental pollution of the USA. Interestingly, our paper represents a completion to the existing literature on three levels at least. First

BACKGROUND: Identifying potential risk factors related to severe COVID-19 outcomes is important. Repeated intermittent antibiotic use is known be associated with adverse outcomes. This study aims to examine whether prior frequent antibiotic exposure

Lung pathophysiology in long COVID https://bit.ly/3IaPyS8.

CONCLUSION: These recommendations that were developed through evidence synthesis and formal consensus process provide guidance for an enhanced primary series COVID-19 vaccination in PRDs.

CONCLUSIONS: Primary virus detection was associated with higher risk of subsequent virus detection within the first 90 days after primary detection.

In this paper, we develop a mixture of autoregressive (MoAR) process model with time varying and freely indexed covariates under the flexible class of two-piece distributions using the scale mixtures of normal (TP-SMN) family. This novel family of

Since the onset of the COVID-19 pandemic, the shortcomings and neglected weaknesses of public health systems have risen to the surface, emphasizing the need for new approaches to designing and delivering public health training. Higher education

Declining trends in vaccine confidence come at a time when routine immunization coverage for children has slumped to a decades-long low. With some of the largest losses in confidence experienced among young adults, this is a concerning trend with the

Immune checkpoint inhibitors (ICIs) therapy have revolutionized advanced lung cancer care. Interestingly, the host responses for patients received ICIs therapy are distinguishing from those with cytotoxic drugs, showing potential initial transient

INTRODUCTION: Breast cancer is the most common cancer in women worldwide. One of the treatment choices used in hormone receptor positive and HER2 expression negative metastatic breast cancer is cyclin dependent kinase 4/6 (CDK) inhibitors. There are